The unveiling of a novel mechanism of resistance to immunotherapy targeting HER2

Handcuffing the culprit cancer: Immunotherapy for cold tumors with trispecific antibody

Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer

Suppressive immune cells' metabolic vulnerability may be targeted for cancer immunotherapy